Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient.
Publication Title
Anti-cancer drugs
Document Type
Article
Publication Date
11-1-2019
Keywords
Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Laparoscopy; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Ovarian Neoplasms; Pleural Effusion; Tomography, X-Ray Computed; Vaccinia virus
Abstract
Heavily pretreated ovarian cancer patients become progressively chemoresistant, and thereafter, only scant treatments potentially accord reasonable, albeit limited clinical efficacy. We describe a case involving a 67-year-old ovarian cancer patient who underwent multiple lines of chemotherapy and presented with recurrent disease and a CA-125 of 4112 U/mL. Thenceforth, she was treated with GL-ONC1 oncolytic viral therapy that was administered laparoscopically in accordance with a clinical trial. The patient subsequently received chemotherapy and during the fourth cycle, her CA-125 decreased to 99 U/mL; moreover, a computed tomography scan of the pelvis exhibited significant disease reduction. Viral therapy hypothetically confers significant promise in the treatment of recurrent ovarian cancer, especially in patients who remain unresponsive to traditional medications.
Clinical Institute
Cancer
Clinical Institute
Women & Children
Specialty/Research Institute
Oncology
Specialty/Research Institute
Obstetrics & Gynecology
Specialty/Research Institute
Diagnostic Imaging
